ABL Bio Inc.

KOSDAQ:A298380 Stock Report

Market Cap: ₩6.1t

ABL Bio Future Growth

Future criteria checks 3/6

ABL Bio is forecast to grow earnings and revenue by 49% and 11.1% per annum respectively. EPS is expected to grow by 47.2% per annum. Return on equity is forecast to be -12.8% in 3 years.

Key information

49.0%

Earnings growth rate

47.23%

EPS growth rate

Biotechs earnings growth24.3%
Revenue growth rate11.1%
Future return on equity-12.84%
Analyst coverage

Low

Last updated29 Apr 2026

Recent future growth updates

Recent updates

Analysis Article Aug 08

Health Check: How Prudently Does ABL Bio (KOSDAQ:298380) Use Debt?

KOSDAQ:A298380 1 Year Share Price vs Fair Value Explore ABL Bio's Fair Values from the Community and select yours...
Analysis Article Mar 26

ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Nov 20

Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

ABL Bio Inc. ( KOSDAQ:298380 ) shares have had a horrible month, losing 30% after a relatively good period beforehand...
Analysis Article May 29

Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Feb 26

Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Mar 31

We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jan 20

Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

We believe investing is smart because history shows that stock markets go higher in the long term. But not every stock...
Analysis Article Dec 16

Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

KOSDAQ:A298380 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202886,000-23,00016,00034,0002
12/31/2027114,5401,75019,40021,3805
12/31/202694,1201,00035,00052,0005
3/31/202690,321-24,1366,43319,955N/A
12/31/202579,350-37,806-61,924-41,253N/A
9/30/202588,437-28,645-54,641-33,185N/A
6/30/202594,931-20,522-44,776-23,584N/A
3/31/202527,631-71,706-95,079-80,249N/A
12/31/202433,403-55,529-78,461-69,403N/A
9/30/202432,321-49,041-81,451-71,189N/A
6/30/202432,955-40,003-73,541-64,894N/A
3/31/202433,103-38,952-67,776-60,555N/A
12/31/202365,547-2,647-34,206-28,362N/A
9/30/202367,446-7,9511,2524,155N/A
6/30/202397,25423,6085,5348,498N/A
3/31/2023104,80336,1019,86312,230N/A
12/31/202267,3013,20969,74672,132N/A
9/30/202257,9944,35243,64544,605N/A
12/31/20215,332-43,558-41,871-40,605N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A298380 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: A298380 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A298380 is expected to become profitable in the next 3 years.

Revenue vs Market: A298380's revenue (11.1% per year) is forecast to grow slower than the KR market (16.6% per year).

High Growth Revenue: A298380's revenue (11.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A298380 is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/18 01:57
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABL Bio Inc. is covered by 4 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Haesoon KwonEugene Investment & Securities Co Ltd.
Hee Ryeong JungKyobo Securities Co., Ltd